For example, Abdelfatah and colleagues evaluated the clinical utility of a different lymphocyte subset, circulating CX3CR1+CD8+ T cells, as a predictive marker of response to chemoimmunotherapy in 29 patients with stage II-IV NSCLC [82]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.